Two-month-old C57BL/6J mice orally supplemented with B. breve MCC1274 for four months mitigated AD-like pathologies by decreasing soluble Aβ42 levels, inhibiting tau phosphorylation, attenuating neuroinflammation, and improving synaptic protein levels in the hippocampus. Here, MAPT is linked to Alzheimer disease.